[Prostaglandin E1: results and perspectives in clinical practice].
Guseva
N G
NG
D000527:Alprostadil / Q000494:pharmacology / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006331:Heart Diseases / Q000188:drug therapy; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy; D008171:Lung Diseases / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012216:Rheumatic Diseases / Q000188:drug therapy; D014652:Vascular Diseases / Q000188:drug therapy; D014665:Vasodilator Agents / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D000527:Alprostadil